哪里想瘦打哪里！FDA批准Kythera注射药物并购在即

你才双下巴，你全家人都双下巴！所谓大方之心人皆有之。如果说赘肉是每一个希望拥有完美身材的“妹纸”或“汉纸”的作对，那么一个喜感十足的双下巴可谓是这些人的生死不信了。每一分钟，世界各地都有人为自己的一张大饼脸而感到烦恼，虽然拥有一个肉感十足的双下巴捏上去是挺有肉感的，但是还是有很多人的心理素质使其无法忍受一个双下巴之重。您可千万别笑，这甚至不太可能催生造出一个巨量的市场。根据美国黏膜外科手术基金会的事件调查研究成果辨识，68%的美国人对自己的双下巴表示了“厌倦”之情。而有鉴于，除此以外Kythera一些公司向FDA草拟了其专门打倒双下巴的保养品口服式口服ATX-101。这种口服完成了许多“胖纸”梦寐以求的功用，哪里想瘦打哪里，可谓是定点肥胖症。不要以为这种近乎任性的口服只是一个笑话，在FDA下属的黏膜和眼科口服处长会的无记名投票决定中会，专业人士可是以17：0的超高票数相符赞许其上市。毫无疑问是因为这些专业人士中会也有很多饱受双下巴之苦吧。FDA也将计划于当年的5年底13日之前对其这两项最后决定。如果一切顺利的话，Kythera一些公司计划于当年下半年将该产品上市，分析人士预计这一口服的年销售额将超过3亿美元之多。随着保养品口服市场的急剧增大，Kythera一些公司可谓是下了一步好棋。一些公司于去年以8400万美元的价位从其前多家一些公司波鸿控制权会发还了这种口服的全部有权。而Kythera一些公司也希望意在为借此机会在保养品口服市场中会攻城拔寨。就在上个年底，Kythera一些公司和Actelion一些公司达成价值2700万美元的携手协商，开发公司一种失败过的抗黏膜口服，而这种口服被认为确实开发造出一种治疗法病变的口服。详细英文华盛顿邮报：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.